People in England with sickle cell will be able to get the world’s first CRISPR-based medicine under an agreement between the ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell ...
Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...
Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.